This paper focuses on simple synthetic pathways that may help achieve two compounds previously designed by our group, which should preferably target the prion protein involved in Sporadic Fatal Insomnia. This step is necessary for in vitro studies whose relevance is linked to their potential empirical support of the hitherto computational drug design analysis carried out.